Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study.
Sawa K, Ihara Y, Imai T, Sugimoto A, Nagamine H, Ogawa K, Nakahama K, Matsumoto Y, Tani Y, Kaneda H, Mitsuoka S, Kawaguchi T, Shintani A. Sawa K, et al. Among authors: tani y. Clin Lung Cancer. 2024 Mar;25(2):144-150.e3. doi: 10.1016/j.cllc.2023.11.003. Epub 2023 Nov 7. Clin Lung Cancer. 2024. PMID: 38042690
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations.
Izumi M, Sawa K, Oyanagi J, Noura I, Fukui M, Ogawa K, Matsumoto Y, Tani Y, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Nishiyama N, Ohsawa M, Yamamoto N, Koh Y, Kawaguchi T. Izumi M, et al. Among authors: tani y. Transl Oncol. 2021 Jul;14(7):101102. doi: 10.1016/j.tranon.2021.101102. Epub 2021 Apr 27. Transl Oncol. 2021. PMID: 33930847 Free PMC article.
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Kaneda H, Sawa K, Daga H, Okada A, Nakatani Y, Atagi S, Okishio K, Tani Y, Matsumoto Y, Ogawa K, Nakahama K, Izumi M, Mitsuoka S, Kawaguchi T. Kaneda H, et al. Among authors: tani y. Invest New Drugs. 2021 Dec;39(6):1598-1603. doi: 10.1007/s10637-021-01147-w. Epub 2021 Jul 2. Invest New Drugs. 2021. PMID: 34215931 Clinical Trial.
Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.
Nakahama K, Kaneda H, Osawa M, Fukui M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: tani y. Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18. Cancer Sci. 2022. PMID: 35722982 Free PMC article.
Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: tani y. Thorac Cancer. 2022 Aug;13(16):2309-2317. doi: 10.1111/1759-7714.14560. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808895 Free PMC article.
SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.
Nakahama K, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: tani y. Transl Lung Cancer Res. 2022 Dec;11(12):2438-2451. doi: 10.21037/tlcr-22-496. Transl Lung Cancer Res. 2022. PMID: 36636414 Free PMC article.
970 results